Cytokinetics (MIL:1CYTK) E10: €-3.59 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CYTK Cytokinetics Inc MIL:1CYTK
32 GF Score
Price €62.98
GF Value €196.26
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Cytokinetics E10?

Cytokinetics MIL:1CYTK 32 E10 is €-3.59 as of Jun. 2026. GuruFocus rates MIL:1CYTK with a GF Score™ of 32/100 and a GF Value™ of €196.26 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cytokinetics's adjusted earnings per share data for the three months ended in Jun. 2026 was €-1.294. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-3.59 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was -21.00% per year. During the past 5 years, the average E10 Growth Rate was -15.00% per year. During the past 10 years, the average E10 Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Cytokinetics was 42.20% per year. The lowest was -21.00% per year. And the median was 5.20% per year.

As of today (2026-09-17), Cytokinetics's current stock price is €62.98. Cytokinetics's E10 for the quarter that ended in Jun. 2026 was €-3.59. Cytokinetics's Shiller PE Ratio of today is .


Cytokinetics  (MIL:1CYTK) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cytokinetics E10 Related Terms


Cytokinetics E10 Historical Data

* Premium members only.

The historical data trend for Cytokinetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytokinetics E10 Chart

Cytokinetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.50 -1.78 -2.22 -2.73 -3.26

Cytokinetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.98 -3.19 -3.29 -3.45 -3.59

MIL:1CYTK vs IONS, APGE, KYMR: E10 Comparison

For the Biotechnology subindustry, Cytokinetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytokinetics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Shiller PE Ratio falls into.


MIL:1CYTK
32GF Score
Cytokinetics Inc MIL:1CYTK
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytokinetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cytokinetics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.2942/333.9520*333.9520
=-1.294

Current CPI (Jun. 2026) = 333.9520.

Cytokinetics Quarterly Data

per share eps CPI Adj_EPS
201609 0.690 241.428 0.954
201612 0.148 241.432 0.205
201703 -0.582 243.801 -0.797
201706 -0.545 244.955 -0.743
201709 -0.511 246.819 -0.692
201712 -0.637 246.524 -0.863
201803 -0.456 249.554 -0.610
201806 -0.428 251.989 -0.567
201809 -0.347 252.439 -0.458
201812 -0.424 251.233 -0.564
201903 -0.472 254.202 -0.620
201906 -0.496 256.143 -0.646
201909 -0.454 256.759 -0.590
201912 -0.468 256.974 -0.608
202003 -0.604 258.115 -0.781
202006 -0.621 257.797 -0.805
202009 -0.040 260.280 -0.051
202012 -0.520 260.474 -0.667
202103 -0.549 264.877 -0.693
202106 -0.712 271.696 -0.875
202109 -0.804 274.310 -0.978
202112 -0.318 278.802 -0.381
202203 -0.938 287.504 -1.090
202206 -0.217 296.311 -0.244
202209 -1.507 296.808 -1.695
202212 -1.423 296.797 -1.602
202303 -1.286 301.836 -1.423
202306 -1.234 305.109 -1.351
202309 -1.238 307.789 -1.344
202312 -1.285 306.746 -1.399
202403 -1.226 312.332 -1.311
202406 -1.219 314.175 -1.295
202409 -1.242 315.301 -1.315
202412 -1.191 315.605 -1.260
202503 -1.294 319.799 -1.351
202506 -0.992 322.561 -1.027
202509 -2.184 324.800 -2.245
202512 -1.284 324.054 -1.324
202603 -1.429 330.213 -1.445
202606 -1.294 333.952 -1.294

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-3.59 mean?
Cytokinetics (MIL:1CYTK) has a E10 of €-3.59 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cytokinetics and its competitors.
Is Cytokinetics' E10 too high?
Cytokinetics' current E10 is €-3.59. Overall, Cytokinetics has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cytokinetics' E10 compare to IONS and APGE?
Cytokinetics' E10 of €-3.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cytokinetics and its competitors. Cytokinetics's current E10 is €-3.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytokinetics stock overvalued right now?
Based on GuruFocus' analysis, Cytokinetics (MIL:1CYTK) is currently considered Possible Value Trap. The stock's GF Value™ is €196.26, compared to a current price of €62.98 — trading 67.9% below its estimated fair value. The current E10 is €-3.59. Cytokinetics' overall GF Score™ is 32/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cytokinetics (MIL:1CYTK), the current E10 is €-3.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cytokinetics (MIL:1CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of €62.98 is trading 67.9% below its estimated GF Value™ of €196.26. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for MIL:1CYTK:

  • E10: €-3.59
  • GF Value™: €196.26 vs. price of €62.98 (67.9% below fair value)
  • GF Score™: 32/100 with 7 warning signs

No single metric tells the full story. See the MIL:1CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cytokinetics Business Description

Other Exchanges CYTK:USAKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
32GF Score

Get the complete analysis for MIL:1CYTK

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.98
Price
€196.26
GF Value